Search Results - "Bottiglieri, Sal"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation by Nelson, Ryan S, Seligson, Nathan D, Bottiglieri, Sal, Carballido, Estrella, Cueto, Alex Del, Imanirad, Iman, Levine, Richard, Parker, Alexander S, Swain, Sandra M, Tillman, Emma M, Hicks, J Kevin

    Published in Cancers (29-03-2021)
    “…Multi-gene assays often include and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However,…”
    Get full text
    Journal Article
  2. 2

    PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience by Miao, Ruoyu, Blue, Kirsten, Sommerer, Katelyn, Shah, Anand, Bottiglieri, Sal, Del Cueto, Alex, Berry, Darcy K, Ho, Teresa T, Hicks, James Kevin, Kim, Dae Won

    Published in Cancers (11-10-2024)
    “…Limited data are available regarding the anticancer activity of PARP inhibitors (PARPis) in pancreatic cancer with mutations in HRR genes other than and . We…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Blood pressure control in patients receiving bevacizumab in an outpatient cancer center by Bottiglieri, Sal, Muluneh, Benyam, Sutphin, Stephanie, Iacovelli, Lew, Adams, Val

    Published in Journal of oncology pharmacy practice (01-12-2011)
    “…Purpose. Hypertension is a common adverse effect of vascular endothelial growth factor (VEGF) signaling inhibitors, such as bevacizumab, with an incidence…”
    Get full text
    Journal Article
  6. 6

    Gemcitabine-induced gouty arthritis attacks by Bottiglieri, Sal, Tierson, Neil, Patel, Raina, Mo, Jae-Hyun, Mehdi, Syed

    Published in Journal of oncology pharmacy practice (01-09-2013)
    “…In this case report, we review the experience of a patient who presented with early stage pancreatic cancer (Stage IIb) who underwent a Whipple procedure and…”
    Get full text
    Journal Article
  7. 7

    Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer by Snyder, Matthew, Bottiglieri, Sal, Almhanna, Khaldoun

    Published in Reviews on recent clinical trials (2018)
    “…Colorectal cancer is one of the most common malignancies in the United States, with a large proportion of patients presenting with metastatic disease or…”
    Get more information
    Journal Article